Apellis Pharmaceuticals Inc (APLS)vsRoyalty Pharma Plc (RPRX)
APLS
Apellis Pharmaceuticals Inc
$41.03
0.00%
HEALTHCARE · Cap: $5.25B
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 121% more annual revenue ($2.44B vs $1.11B). RPRX leads profitability with a 33.9% profit margin vs 12.1%. RPRX trades at a lower P/E of 28.9x. RPRX earns a higher WallStSmart Score of 65/100 (C+).
APLS
Buy50
out of 100
Grade: C-
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.5%
Fair Value
$194.37
Current Price
$41.03
$153.34 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Revenue surging 60.9% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
Trading at 12.7x book value
0.0% earnings growth
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : APLS
The strongest argument for APLS centers on Return on Equity, Revenue Growth. Revenue growth of 60.9% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : APLS
The primary concerns for APLS are P/E Ratio, Price/Book, EPS Growth.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
APLS profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
APLS is growing revenue faster at 60.9% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 50/100), backed by strong 33.9% margins and 11.0% revenue growth. APLS offers better value entry with a 88.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apellis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?